UB638
TargetsLPA
IndicationsAtherosclerotic cardiovascular disease
ClinicalCN - II、US - II
TherapeuticsCardiovascular
ModalitiesNucleic Acid Therapeutics
Exclusive Summary
- • First in modality, clinically validated siRNA product with once-a-year dosing.
- • Global BIC LPA-siRNA with superior potency and durability at low dose.
- • Excellent LPA-siRNA data from Ph1 trial: >90% Lp(a) reduction sustained for 48 weeks in a single dose above 75 mg.
- • No traditional DDI concern with combination usage of small molecules.
Asset Materials
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →